Vertically Integrated Healthcare Model
MedPal AI plc has announced its UK vertically integrated healthcare platform is fully operational, combining AI-powered digital health with human-validated prescribing and robotic pharmacy dispensing. The company generates revenue from multiple sources per patient, including app subscriptions at £3.99/month or £29.99/year, NHS dispensing fees averaging £9.90+ per item, private prescriptions, and clinical consultation fees. In January 2026, MedPal AI dispensed 36,951 items and achieved 7,791 app installs, acquired through various channels such as NHS contracts, direct advertising, and a partnership with Epassi, which provides access to over 11 million employees.
Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes
| MedPal AI plc (AIM: MPAL | Frankfurt: Z1N), the AI-powered digital health and pharmacy services provider, provides this update on its UK vertically integrated platform. After seizing the opportunity to establish the MedPal Limited pharmacy operations in October 2025, the Company's strategy has evolved from being centred on the MedPal app to integrating it with an AI driven triage system and prescribing service. |
The Company's business model uniquely links AI-assisted digital health to regulated pharmacy and clinical services, generating revenue at every patient interaction. This creates strong unit economics that improve with scale
Highlights
- Vertically integrated UK platform is fully operational, merging AI-powered digital health with human-validated prescribing and robotic pharmacy dispensing/delivery.
- Multi-revenue per patient: app subscriptions £3.99/month or £29.99/year, NHS dispensing fees £9.90+ per item, private prescription income, and clinical consultation fees.
- Diverse customer acquisition channels: NHS contracts, DSP licences, direct ads via MedPal.clinic and app, plus Epassi partnership accessing 11m+ employees.
- Bi-directional cross-sell: App users convert to pharmacy patients; pharmacy patients to app subscribers, boosting lifetime value.
- Scale demonstrated: 36,951 items dispensed in January 2026; 7,791 app installs, all paid or on Epassi acquisition pathway (no free tier).
Integrated Model and Revenue Streams
Core to operations is human-in-the-loop prescribing: AI triage is validated by professionals, followed by robotic dispensing and delivery. Each patient potentially yields multiple revenues: recurring app subscriptions , NHS dispensing fees, private prescriptions (e.g., GLP-1 treatments), and consultation fees. 36,951prescription items were dispensed in January, highlighting revenue potential.
Patient Acquisition Channels
Patient growth draws from multiple independent sources for resilience: NHS/DSP contracts for stable volume; direct ads and MedPal.clinic for private services; the MedPal app with 7,791 installs (either paid or Epassi-linked); and Epassi partnerships reaching 11m+ employees, where complimentary access converts to subscriptions while generating pharmacy revenue.
Jason Drummond, CEO of MedPal AI, said:
"MedPal AI's platform uniquely integrates AI, clinicians, and robotic dispensing for end-to-end care and revenue at every step. Diverse channels-from NHS contracts to Epassi's 11m+ employees fuel resilient growth. Our cross-sell flywheel compounds value: app users become pharmacy patients, and vice versa. With 36,951 items dispensed in January and 7,791 app installs, we are well positioned for sustained expansion."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.